"Designing Growth Strategies is in our DNA"

Amyotrophic Lateral Sclerosis Therapeutics Market Size, Share & Industry Analysis, By Drug Type (Tofersen, Edaravone, Riluzole, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacy and Retail & Online Pharmacy), and Regional Forecast, 2024-2032

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI110139

 


To get information on various segments, share your queries with us

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2023

Estimated Year

2024

Forecast Period

2024-2032

Historical Period

2019-2022

Growth Rate

CAGR of 11.3% from 2024-2032

Unit

Value (USD Billion)

 

Segmentation

By Drug Type

  • Tofersen
  • Edaravone
  • Riluzole
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacy
  • Retail & Online Pharmacy

By Region

  • North America (by Drug Type, by Route of Administration, by Distribution Channel, and by Country)
    • U.S.
    • Canada
  • Europe (by Drug Type, by Route of Administration, by Distribution Channel, and by Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (by Drug Type, by Route of Administration, by Distribution Channel, and by Country/Sub-region)
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia Pacific
  • Rest of the World (by Drug Type, by Route of Administration, and by Distribution Channel)
  • 2019-2032
  • 2023
  • 2019-2022
  • 100
Download Free Sample

    man icon
    Mail icon
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann